Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses

European Journal of Endocrinology

Volumn 150, Issue 4, 2004, Pages 547-556

  Schmutzler, Cornelia ^a   Hoang Vu, Cuong ^c   Rüger, Barbara ^b   Köhrle, Josef ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOID DERIVATIVE; THYROXINE DEIODINASE;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; PATHOGENESIS; PRIORITY JOURNAL; RAT; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID FOLLICULAR CARCINOMA; TUMOR DIFFERENTIATION; TUMOR GROWTH; XENOTRANSPLANTATION;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; RATS; RATS, NUDE; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; THYROID NEOPLASMS; TRETINOIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2342564416     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500547     Document Type: Article

References (53)

1. Wolf G. A history of vitamin A and retinoids. FASEB Journal 1996 10 1102-1107.
2. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ & De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000 21 1271-1279.
3. Schmutzler C & Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000 10 393-406.
4. Rastinejad F. Retinoid X receptor and its partners in the nuclear receptor family. Current Opinion in Structural Biology 2001 11 33-38.
5. Torchia J, Glass CK & Rosenfeld MG. Co-activators and co-repressors in the integration of transcriptional responses. Current Opinion in Cell Biology 1998 10 373-383.
6. Love JM & Gudas LJ. Vitamin A differentiation, and cancer. Current Opinion in Cell Biology 1994 6 825-831.
7. Rochaix P, Monteil-Onteniente S, Rochette-Egly C, Caratero C, Voigt JJ & Jozan S. Reduced expression of retinoic acid receptor beta protein (RAR beta) in human papillary thyroid carcinoma: immunohistochemical and Western blot study. Histopathology 1998 33 337-343.
8. Bartsch D, Boye B, Baust C, zur Hausen H & Schwarz E. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor β gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO Journal 1992 11 2283-2291.
9. Houle B, Rochette-Egly C & Bradley WEC. Tumor-suppressive effect of the retinoic acid receptor in human epidermoid lung cancer cells. PNAS 1993 90 985-998.
10. Hayashi K, Yokozaki H, Naka K, Yasui W, Lotan R & Tahara E. Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Japanese Journal of Cancer Research 2001 92 42-50.
11. Naylor SL, Johnson BE, Minna JD & Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small cell lung cancer. Nature 1987 329 451-453.
12. Qiu H, Lotan R, Lippman SM & Xu XC. Lack of correlation between expression of retinoic acid receptor-beta and loss of heterozygosity on chromosome band 3p24 in esophageal cancer. Genes, Chromosomes and Cancer 2000 28 196-202.
13. Bovenzi V, Le NL, Cote S, Sinnett D, Momparler LF & Momparler RL. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine. Anticancer Drugs 1999 10 471-476.
14. Satta MA, Nannim S, Della Casam S & Pontecorvi A. Molecular biology of thyroid neoplasms. Rays 2000 25 151-161.
15. Köhrle J. Local activation and inactivation of thyroid hormones: the deiodinase family. Molecular and Cellular Endocrinology 1999 151 103-119.
16. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. PNAS 2001 98 15044-15049.
17. Köhrle J, Oertel M, Hoang-Vu C, Schnieders F & Brabant G. Type I 5′-deiodinase - a marker for differentiated thyroid carcinoma? Experimental and Clinical Endocrinology 1993 101 60-72.
18. Schreck R, Schnieders F, Schmutzler C & Köhrle J. Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 1994 79 791-798.
19. Goretzki PE, Frilling A, Simon D & Röher HD. Growth regulation of normal thyroids and thyroid tumor in man. Recent Results in Cancer Research 1990 118 48-63.
20. Heldin NE, Cvejic D. Smeds S & Westermark B. Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells. Endocrinology 1991 129 2187-2193.
21. Heldin NE, Gustavsson B, Claesson-Welsh L, Hammacher A, Mark J, Heldin CH et al. Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma line. PNAS 1988 85 9302-9306.
22. Dutkiewicz S, Witeska A & Nauman A. The deiodination of thyroxine to triiodothyronine in the testes of patients with prostate cancer. International Urology and Nephrology 1995 27 81-85.
23. Pachucki J, Ambroziak M, Tanski Z, Luczak J, Nauman J & Nauman A. Type I 5′-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. Journal of Endocrinological Investigation 2001 24 253-261.
24. Murakami M, Araki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T et al. Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 2001 142 2961-2967.
25. 1 integrins and production of proteases. World Journal of Surgery 1992 16 770-776.
26. Leonard JL & Rosenberg IN. Iodothyronine 5′-deiodinase from rat kidney: substrate specificity and the 5′-deiodination of reverse triiodothyronine. Endocrinology 1980 107 1376-1383.
27. Chomczynski P & Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987 162 156-159.
28. Nagayama Y, Kaufman KD, Seto P & Rapoport B. Molecular cloning, sequence, and functional expression of the cDNA for the human thyrotropin receptor. Biochemical and Biophysical Research Communications 1989 165 1184-1190.
29. Libert F, Lefort A, Gerard C, Parmentier M, Perret J, Ludgate M et al. Cloning, sequencing, and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochemical and Biophysical Research Communications 1989 165 1250-1255.
30. Baas F, van Ommen GJ, Bikker H, Arnberg AC & de Vijlder JJ. The human thyroglobulin gene is over 300 kb long and contains introns of up to 64 kb. Nucleic Acids Research 1986 14 5171-5186.
31. Niks M & Otto M. Towards an optimized MTT-assay. Journal of Immunological Methods 1990 130 149-151.
32. Hoang-Vu C, Dralle H, Schröder S, Oertel M, Köhrle J, Hesch R-D et al. The nude rat is established as a model for endocrine studies: regulation of thyroid function and xenotransplantation of a thyroid tumor cell line. Laboratory Animals in Science 1992 42 164-167.
33. Keidel S, Szardenings M & Mueller WH. In vivo biological activity of retinoids partially correlates to their affinity to recombinant retinoic acid receptor α and recombinant cellular retinoic acid binding protein I. European Journal of Biochemistry 1993 212 13-26.
34. Schmutzler C, Winzer R, Meissner-Weigl J & Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochemical and Biophysical Research Communications 1997 240 832-838.
35. Van Herle AJ, Agatep ML, Padua DN III, Totanes TL, Canlapan DV, van Herle HM et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism 1990 71 755-763.
36. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M et al. All-trans retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. Journal of Clinical Endocrinology and Metabolism 2000 85 2889-2896.
37. Del Senno L, Rossi R, Franceschetti P & Degli Uberti EC. Expression of all-trans-retinoic acid receptor RNA in human thyroid cells. Biochemistry and Molecular Biology International 1994 33 1107-1115.
38. Hoang-Vu C, Bull K, Schwarz I, Krause G, Schmutzler C, Aust G et al. Regulation of CD97 protein in thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1999 84 1104-1109.
39. Toyoda N, Zavacki AM, Maia AL, Harney JW & Larsen PR. A novel retinoid X receptor-independent thyroid hormone response element is present in the human type I deiodinase gene. Molecular and Cellular Biology 1995 15 5100-5112.
40. +4 thyroid hormone responsive element. European Journal of Biochemistry 1997 247 288-297.
41. Schmutzler C, Schmitt TL, Glaser F, Loos U & Köhrle J. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Molecular and Cellular Endocrinology 2002 189 145-155.
42. Schmutzler C, Brtko J, Winzer R, Jakobs TC, Meissner J, Simon D et al. Functional retinoid and thyroid hormone receptors in human thyroid cell lines and tissues. International Journal of Cancer 1998 76 368-376.
43. Tang W, Nakamura Y, Zuo H, Yasuoka H, Yang Q, Wang X et al. Differentiation, proliferation and retinoid receptor status of papillary carcinoma of the thyroid. Pathology International 2003 53 204-213.
44. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World Journal of Surgery 1998 22 569-574.
45. Simon D, Krausch M, Segering J, Groth P, Görges R, Grünwald F et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer - final results of a pilot study. European Journal of Nuclear Medicine and Molecular Imaging 2002 29 775-782.
46. Körber C, Schmutzler C, Rendl J, Koehrle J, Griesser H, Simon D et al. Increased I-131 uptake in local recurrence and distant metastases after second treatment with retinoic acid. Clinical Nuclear Medicine 1999 24 849-851.
47. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. Journal of Nuclear Medicine 1998 39 1903-1906.
48. Grünwald F, Pakos E, Bender H, Menzel C, Otte R, Palmedo H et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. Journal of Nuclear Medicine 1998 39 1555-1558.
49. Grüning T, Tiepolt C, Zöphel K, Bredow J, Kropp J & Franke WG. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? European Journal of Endocrinology 2003 148 395-402.
50. Boerner AR, Petrich T, Weckesser E, Fricke H, Hofmann M, Otto D et al. Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging 2002 29 231-236.
51. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997 277 965-968.
52. +/I-symporter gene methylation status. Journal of Clinical Endocrinology and Metabolism 1999 84 2449-2457.
53. Huang Y, de la Chapelle A & Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. International Journal of Cancer 2003 104 735-744.